Literature DB >> 8314829

Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement.

G D Paiement1, S J Wessinger, R Hughes, W H Harris.   

Abstract

The efficacy and safety of routine use of adjusted low-dose warfarin for twelve weeks--without sonography or venography--for the prophylaxis of deep-vein thrombosis after total hip replacement was assessed in 268 patients (134 men and 134 women) who were between the ages of forty and eighty-five years (average, sixty-one years). The patients were given warfarin orally both before and after the operation. The initial dose was usually ten milligrams on the night before the operation and five milligrams on the night after the operation. Thereafter, the dose was adjusted to keep the prothrombin time between fourteen and sixteen seconds. The control time was ten to twelve seconds. The partial thromboplastin time was also measured, and the dose of warfarin was reduced if the value was more than fifty seconds. All 268 patients continued to take low-dose warfarin for twelve weeks after the operation. There were 170 primary and ninety-eight revisional total hip-replacement operations. Thirty-four patients (13 per cent) had a history of thromboembolic disease or venous stasis in a lower limb. Neither phlebography nor sonography was done routinely. All of the patients were followed for six months after the operation. There were no fatal pulmonary emboli during the period of the study and no known pulmonary emboli after any patient was discharged from the hospital. Two non-fatal pulmonary emboli were identified, both during hospitalization. Ten patients (4 per cent) had an episode of major bleeding--a wound hematoma in nine and a gastrointestinal hemorrhage in one--during hospitalization.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314829     DOI: 10.2106/00004623-199306000-00010

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

1.  Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

Authors:  A Planes; N Vochelle; J Y Darmon; M Fagola; M Bellaud; D Compan; E Saliba; N Weisslinger; Y Huet
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty.

Authors:  Bun Jung Kang; Young-Kyun Lee; Hee Joong Kim; Yong-Chan Ha; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2011-07-12       Impact factor: 4.176

Review 3.  Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management.

Authors:  G P Samsa; D B Matchar
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.

Authors:  Alejandro González Della Valle; Saurabh Khakharia; Charles J Glueck; Nicole Taveras; Ping Wang; Robert N Fontaine; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-11-26       Impact factor: 4.176

5.  Results of adjusted-dose heparin for thromboembolism prophylaxis in knee replacement compared to those found for its use in hip fracture surgery and elective hip replacement.

Authors:  David Yen; William Weiss
Journal:  Iowa Orthop J       Date:  2007

6.  Deep Vein Thrombosis Prophylaxis after Total Hip Arthroplasty in Asian Patients.

Authors:  Jun-Shik Kim
Journal:  Hip Pelvis       Date:  2018-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.